The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

The company is still seeking strategic options for its development programs, including nana-val, which it was testing in EBV-positive refractory lymphoma.

The firm will make its artificial intelligence-based Lunit SCOPE IO platform available to SITC member researchers.

The Department of Health and Social Care is gauging whether AI technology can increase the number of patients screened by each radiologist.